Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 1, 2021, Akebia Therapeutics, Inc. (the "Company") filed a Current
Report on Form 8-K (the "Initial 8-K") disclosing that on and effective
November 1, 2021, the Board of Directors of the Company (the "Board") increased
the Board's size from eight to nine directors and elected Ron Frieson as a Class
I director. At the time of filing the Initial 8-K, the Board had not made a
determination regarding any committee assignments for Mr. Frieson.
This Current Report on Form 8-K/A amends the Initial 8-K to disclose that on and
effective December 10, 2021, upon the recommendation of the Nominating and
Corporate Governance Committee of the Board (the "NCG Committee"), the Board
increased the size of the NCG Committee from three members to four members and
appointed Mr. Frieson as a member of the NCG Committee.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses